相关实验视频
Updated: Jun 19, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
在患心力衰竭的模型中使用生长激素分泌剂治疗:对心室和肌细胞功能的影响
1Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston 29425, USA.
Circulation
|February 24, 2001
概括
增长激素分泌剂 (GHS) 在充血性心力衰竭 (CHF) 模型中改善了左心室 (LV) 功能. GHS治疗增强了LV重塑和肌细胞收缩能力,表明了治疗心血管衰竭的潜力.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 增长激素 (GH) 和类似胰岛素的增长因子-1 在充血性心力衰竭 (CHF) 中影响左心室 (LV) 功能.
- 这项研究研究了口服GH分泌剂 (GHS) 对内源GH释放的影响及其对LV功能和肌细胞收缩性的影响,在正在发展的CHF模型中.
研究的目的:
- 为了确定口服活性GH分泌剂 (GHS) 对左心室 (LV) 功能和肌细胞收缩性的影响.
- 评估GHS诱导的内源性GH释放对LV重塑在发展充血性心力衰竭 (CHF) 的模型中的影响.
主要方法:
- 通过快速节奏诱导的CHF的猪被GHS (CP-424,391) 治疗,或作为对照.
- 评估了LV分数缩短,峰值壁应力,LV质量与体重的比率,以及肌细胞缩短的速度.
主要成果:
- 与未经治疗的CHF猪相比,GHS治疗改善了LV的分数缩短,并减少了峰值壁应力.
- GHS 增加了44%的 LV 质量与体重比,并提高了肌细胞缩短的速度.
- 未经治疗的CHF猪显示LV分数缩短减少,峰壁应力增加.
结论:
- 在CHF模型中,GHS治疗改善了LV功能,这可能是由于对心肌重塑和收缩过程的有利影响.
- GH分泌物显示出治疗充血性心力衰竭 (CHF) 的潜力.
- 需要进一步的研究来探索GH分泌剂在心血管疾病管理中的治疗作用.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...